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PLINICAL RESEARCH Clinical Trial
heolytic Thrombectomy With
ercutaneous Coronary Intervention for
nfarct Size Reduction in Acute Myocardial Infarction
0-Day Results From a Multicenter Randomized Study
rshad Ali, MD,* David Cox, MD,† Nabil Dib, MD,‡ Bruce Brodie, MD,§ Daniel Berman, MD,
avin Gupta, MD,§ Kevin Browne, MD,¶ Robert Iwaoka, MD,† Michael Azrin, MD,#
wight Stapleton, MD,* Cindy Setum, PHD,** Jeffrey Popma, MD,†† for the AIMI Investigators
ayre, Pennsylvania; Charlotte and Greensboro, North Carolina; Phoenix, Arizona; Los Angeles, California;
akeland, Florida; Farmington, Connecticut; Minneapolis, Minnesota; and Boston, Massachusetts
OBJECTIVES The goal of this work was to determine whether rheolytic thrombectomy (RT) as an adjunct
to primary percutaneous coronary intervention (PCI) reduces infarction size and improves
myocardial perfusion during treatment of ST-segment elevation myocardial infarction
(STEMI).
BACKGROUND Primary PCI for STEMI achieves brisk epicardial flow in most patients, but myocardial
perfusion often remains suboptimal. Distal embolization of thrombus during treatment may
be a contributing factor.
METHODS This prospective, multicenter trial enrolled 480 patients presenting within 12 h of symptom
onset and randomized to treatment with RT as an adjunct to PCI (n  240) or to PCI alone
(n  240). Visible thrombus was not required. The primary end point was infarct size
measured by sestamibi imaging at 14 to 28 days. Secondary end points included final
Thrombolysis In Myocardial Infarction (TIMI) flow grade, tissue myocardial perfusion
(TMP) blush, ST-segment resolution, and major adverse cardiac events (MACE), defined as
the occurrence of death, new Q-wave myocardial infarction, emergent coronary artery bypass
grafting, target lesion revascularization, stroke, or stent thrombosis at 30 days.
RESULTS Final infarct size was higher in the adjunct RT group compared with PCI alone (9.8 
10.9% vs. 12.5  12.13%; p  0.03). Final TIMI flow grade 3 was lower in the adjunct
RT group (91.8% vs. 97.0% in the PCI alone group; p  0.02), although fewer patients
had baseline TIMI flow grade 3 in the adjunct RT group (44% vs. 63% in the PCI alone
group; p  0.05). There were no significant differences in TMP blush scores or
ST-segment resolution. Thirty-day MACE was higher in the adjunct RT group (6.7% vs.
1.7% in the PCI alone group; p  0.01), a difference primarily driven by very low
mortality rate in patients treated with PCI alone (0.8% vs. 4.6% in patients treated with
adjunct RT; p  0.02).
CONCLUSIONS Despite effective thrombus removal, RT with primary PCI did not reduce infarct size or
improve TIMI flow grade, TMP blush, ST-segment resolution, or 30-day MACE. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.044Coll Cardiol 2006;48:244–52) © 2006 by the American College of Cardiology Foundation
t
c
R
i
d
p
a
s
t
p
t
s
u
trimary percutaneous coronary intervention (PCI) in pa-
ients with ST-segment elevation myocardial infarction
STEMI) results in higher coronary reperfusion rates and
mproved clinical outcomes than fibrinolytic therapy (1).
espite its value, conventional PCI using balloons and
tents alone may dislodge thrombotic material adherent to
From the *Robert Packer Hospital, Sayre, Pennsylvania; †Presbyterian Hospital,
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eart Care, Greensboro, North Carolina; Cedars-Sinai Medical Center, Los
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ersity of Connecticut, Farmington, Connecticut; **Possis Medical, Inc., Minneap-
lis, Minnesota; and the ††Brigham and Women’s Hospital, Boston, Massachusetts.
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ossis Medical Inc. David Holmes, Jr., MD, FACC, served as guest editor for this
eport.c
Manuscript received July 13, 2005; revised manuscript received February 28, 2006,
ccepted March 2, 2006.he ruptured plaque, causing distal embolization and micro-
irculatory impairment and limiting myocardial salvage.
educed myocardial perfusion despite normal coronary flow
s associated with a reduced long-term survival, and can be
etected using a variety of methods, including angiographic
erfusion grades, persistence in the ST-segment elevation,
nd noninvasive imaging modalities, such as sestamibi
cintigraphy (2,3).
Rheolytic thrombectomy (RT) with the AngioJet cathe-
er (Possis Medical, Inc., Minneapolis, Minnesota) is a
roven technique for the removal of thrombus. As shown in
he VEGAS-2 (Vein Graft AngioJet) trial, adjunct RT was
afer and more effective than an extended local infusion of
rokinase for the treatment of angiographically evident
hrombus in saphenous vein grafts (SVGs) and native
oronary arteries (4). As a result of this study, the AngioJet
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July 18, 2006:244–52 Thrombectomy and PCI in Acute MIT catheter (Possis Medical, Inc.) was approved for use in
he U.S. on March 12, 1999, for treatment in thrombus-
ontaining native coronary arteries and SVGs. Plaque rup-
ure and angiographic thrombus formation are central to the
athogenesis of STEMI, but the extent of the thrombus
urden is often not apparent at the time of initial angiog-
aphy. Dislodgement of the thrombotic material during PCI
nd the ensuing complications of “no reflow” and distal
mbolization may increase the myocardial infarction (MI)
ize. Based on a favorable initial experience using adjunct
T in patients with acute MI (5,6), we sought to determine
hether RT as an adjunct to PCI in treatment of STEMI
ould lessen the degree of myocardial necrosis, as assessed
y sestamibi infarct size and myocardial perfusion measured
y tissue myocardial perfusion (TMP) blush and ST-
egment resolution.
ETHODS
tudy design and patients. The AIMI (AngioJet Rheo-
ytic Thrombectomy In Patients Undergoing Primary An-
ioplasty for Acute Myocardial Infarction) study was a
rospective, multicenter trial that randomly assigned pa-
ients to treatment with RT as an adjunct to conventional
CI or to conventional PCI alone. Patients were considered
ligible for enrollment if they were 18 years of age;
resented with anterior MI (new ST-segment elevation of
1 mm in at least 2 contiguous leads within V1 to V6) or
arge inferior MI (new ST-segment elevation of 1 mm in
contiguous leads of II, III, and aVF); presented within
2 h of symptom onset; and had a reference coronary artery
2.0 mm in diameter. Patients were excluded if they had
nown prior ejection fraction 35%, cardiogenic shock
systolic blood pressure 80 mm Hg and requiring inotro-
ic support), contraindication to treatment with glyco-
rotein IIb/IIIa inhibitors, major surgery within the preced-
ng 6 weeks, or history of stroke within 30 days or any
Abbreviations and Acronyms
AIMI  AngioJet Rheolytic Thrombectomy In
Patients Undergoing Primary Angioplasty for
Acute Myocardial Infarction trial
CABG  coronary artery bypass graft
DSMB  Data and Safety Monitoring Board
ECG  electrocardiogram
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal lumen diameter
PCI  percutaneous coronary intervention
RT  rheolytic thrombectomy
SPECT  single-photon emission computed tomography
STEMI  ST-segment elevation myocardial infarction
SVG  saphenous vein graft
TIMI  Thrombolysis In Myocardial Infarction
TLR  target lesion revascularization
TMP  tissue myocardial perfusionistory of hemorrhagic stroke. Study enrollment did not iequire angiographically visible thrombus. Randomization
ccurred after angiographic confirmation of the reference
oronary artery diameter.
All participating study sites received approval from their
ocal hospital investigational review boards before beginning
nrollment. Informed consent was obtained from all pa-
ients before their inclusion in the study.
escription of the RT and PCI procedure. The RT
ystem consists of a drive unit control console, a disposable
ump set, and a disposable single-use RT catheter, as
escribed previously (7). The 5-F LF140 RT catheter
Possis Medical, Inc.) was initially used in 20 randomized
atients and was replaced with the 4-F XMI RT catheter
Possis Medical, Inc.) for all remaining patients. Both
atheter models are indicated for intracoronary use and were
o be used in the study in accordance with the approved
nstructions for use (8).
After diagnostic angiography confirmed vessel size 2.0
m, patients randomized to RT received treatment. Place-
ent of a temporary pacing wire was recommended before
nitiating treatment. The RT catheter was advanced over a
.014-inch guidewire that had been positioned across the
arget lesion and into the distal coronary artery. The catheter
as activated and 1 or more passes through the target lesion
ere made, as assessed by the operator. In lesions without
lear angiographically evident thrombus, a minimum of 3
low passes through and at least 10 mm distal to the lesion
ere to be made.
Definitive PCI with balloon angioplasty and/or stenting
as performed immediately after RT. Control patients were
reated with standard PCI without RT. Choice of coronary
tents was at the discretion of individual operators. Use of
mbolic protection devices or other thrombectomy devices
as not allowed. Standard 12-lead electrocardiograms
ECG) were obtained at the time of initial evaluation and at
0 min after the procedure (ECGs obtained at up to 180
in were allowed).
oncomitant medical therapy and follow-up. Eptifibatide
Millennium Therapeutics, Inc., Cambridge, Massachu-
etts) was started either in the emergency room or admin-
stered in the catheterization laboratory for all patients (9).
ll patients received oral aspirin 325 mg, clopidogrel 300
g loading dose was given before the procedure, and
lopidogrel 75 mg daily was continued for at least 4 weeks
hereafter. Ticlopidine, 500 mg loading dose and 250 mg
wice a day dose was given in the event of intolerance to
lopidogrel. Unfractionated heparin was administered
uring the procedure to attain an activated clotting time
f 250 s. Use of beta-adrenergic blockers, nitroglycerin,
nd angiotensin-converting enzyme inhibitors before and
fter the procedure was at the discretion of individual
hysicians.
tudy end points and analysis. The primary end point was
nfarct size measured by Tc 99m sestamibi imaging at 14 to
8 days after procedure. Secondary angiographic end points
ncluded post-procedure Thrombolysis In Myocardial In-
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Thrombectomy and PCI in Acute MI July 18, 2006:244–52arction (TIMI) flow grade, TMP blush, corrected TIMI
rame count, and procedural complications. Secondary clin-
cal end points included the frequency of complete (70%)
T-segment resolution 90 min after PCI, left ventricular
jection fraction (acquired at time of nuclear imaging), and
0-day major adverse cardiac events (MACE), defined as
he occurrence of death, new Q-wave MI, emergent
oronary artery bypass grafting (CABG), target lesion
evascularization (TLR), stroke, or stent thrombosis.
-wave MI was defined as MI with development of new
waves in 2 or more leads, and elevated creatine
inase-MB. Emergent CABG was defined as surgery
erformed on an urgent basis within 24 h of the index
CI, for recurrent ischemia.
An independent clinical events committee adjudicated
ACE, perforation, pericardial hemorrhage, tamponade,
nd device failures. A Data and Safety Monitoring Board
DSMB) assessed blinded randomized data at prespecified
nterim reviews using predetermined stopping rules for
emonstrated superiority in 1 treatment group. After each
nterim review, the DSMB recommended that the study
ontinue without modification.
nfarct size measurement. A resting Tc-99m sestamibi-
ated single-photon emission computed tomography
SPECT) myocardial perfusion imaging protocol was per-
ormed, after validation of each participating site by the
uclear Core Laboratory (Cedars-Sinai Medical Center,
os Angeles, California) before study enrollment. All raw
cquisition data were uniformity- and center-of-rotation-
orrected and forwarded to the Core Laboratory for pro-
essing by staff blinded to the treatment assignment. The
otal perfusion deficit was determined using a QPS module
hat compares the amount of radioactivity on a pixel-by-
ixel basis within the left ventricular myocardium to the
ower limit of normal distribution derived in patients with a
ow likelihood of coronary artery disease (10), and was used
s the measure of the infarct size. Left ventricular ejection
raction, end-diastolic and end-systolic volumes were mea-
ured using the software program QGS (Cedars-Sinai
edical Center) (11).
ngiographic analysis. Standard image acquisition was
erformed at the clinical sites using 2 or more angiographic
rojections of the coronary occlusion. Angiograms were to
e obtained at baseline, after guidewire recanalization, after
T, and after stent deployment, and then forwarded to the
ngiographic Core Laboratory (Brigham and Women’s
ospital, Inc., Boston, Massachusetts). Thrombolysis in
yocardial Infarction flow grades, TMP blush grades, and
orrected TIMI frame counts were determined according to
reviously defined criteria (12–14). The TIMI frame count
as corrected for the frame acquisition rate but not for the
essel location. For TIMI flow grade 0/1 at baseline, 150
rames were imputed. Thrombus was graded using an
rdinal scale: grade 0: no thrombus present; grade 1:
ossible thrombus, characteristics include reduced contrast
ensity, haziness, irregular lesion contour or a smooth Ponvex meniscus at the site of total occlusion; grade 2: small
hrombus, greater dimension of thrombus is1/2 the vessel
iameter; grade 3: moderate thrombus, greater linear di-
ension is 1/2 but 2 vessel diameters; grade 4: large
hrombus, largest dimension is2 vessel diameters; grade 5:
otal vessel occlusion.
Using the contrast-filled injection catheter as the calibra-
ion source, quantitative angiographic analysis was per-
ormed using a validated automated edge detection algo-
ithm (Medis CMS, Leiden, the Netherlands). Selected
mages for analysis were identified using angiographic pro-
ections that demonstrated the stenosis in an unforeshort-
ned view, minimized the degree of vessel overlap, and
isplayed the stenosis in its “sharpest and tightest” view. A
-mm segment of reference diameter proximal and distal to
he stenosis was used to calculate the average reference
essel diameter at baseline and after stent dilatation. Min-
mal lumen diameter (MLD) was measured at these same
oints. Total occlusions were assigned a MLD of 0 mm and
100% diameter stenosis.
CG analysis. Electrocardiograms were forwarded to the
CG Core Laboratory (Guthrie Clinic/Robert Packer
ospital, Sayre, Pennsylvania) and analyzed by reviewers
linded to treatment assignment and angiographic and
linical end points, using a hand-held electronic caliper. The
T-segment was measured 40 ms after the J point, and the
um of ST-segment deviation was determined before and
fter intervention. The percent resolution of ST-segment
eviation was calculated and categorized using the Schröder
lassification as complete (70%), partial (30% to 70%), or
bsent (30%) (15).
tatistical methods. All continuous measurements were
ummarized descriptively by treatment group; t tests were used
o test for differences in treatment means. Dichotomous
utcomes were presented as proportions of subjects per treat-
ent group and tested for differences using Fisher exact tests.
rdinal results (TIMI flow and blush grades) were presented
s proportions of subjects per treatment group and tested for
roup differences using Cochran-Mantel-Haenszel mean score
ests. Cochran-Mantel-Haenszel tests were also used when
esting for group difference in final TIMI flow and blush
rades, when results were stratified by baseline level. The
ignificance level of all statistical tests was set at p  0.05.
nalyses were by intention-to-treat and were performed with
AS version 8.2 (SAS Institute, Inc., Cary, North Carolina).
he sample size of 480 patients assumed 90% nuclear image
scertainment (10% lost to follow-up) and detection of a
0% treatment effect with 80% power.
ESULTS
tudy population. The study randomized 480 patients
rom 31 contributing sites in the U.S. and Canada from July
6, 2001 to January 21, 2004 (Appendix). Patients were
reated with either RT as an adjunct to PCI (n  240) or
CI alone (n  240). Baseline demographic, clinical, and
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July 18, 2006:244–52 Thrombectomy and PCI in Acute MIesion characteristics were similar for both groups (Tables 1
nd 2). As expected, use of temporary pacemakers was greater
n the adjunct RT group, because prior experience has
hown that bradycardia may be observed during activation
f the RT catheter (4,7). Although crossover treatment was
ot permitted by protocol, 6 patients received crossover RT
reatment. Moderate-to-large thrombus was present in a
inority of patients at baseline: 21.3% in the adjunct RT
roup and 19.6% in the PCI alone group. Of note, baseline
IMI flow grade 3 was present in significantly more
atients in the PCI alone group (Tables 3 to 5).
rocedure and angiographic results. The RT catheter was
uccessfully delivered in 95% of cases. The unsuccessful
eliveries were attributed to: delivery not attempted due
o patient deterioration (n  11), unable to cross the
esion with a guidewire (n  2), unable to set up the RT
ystem (n  2), and attempted but unsuccessful delivery
f the RT catheter (n  4). Complete (88%) or partial
7%) thrombus removal was achieved, as assessed by the
perator. The mean number of passes made with the RT
atheter was 3 (range  1 to 9), using a distal-to-proximal
pproach in 52% and a proximal-to-distal approach in 48%.
otal procedure time was greater in the adjunct RT group
Table 1).
Quantitative angiographic analysis showed a higher inci-
ence of final TIMI flow grade 3 in the PCI alone group,
lthough there were significantly more patients with base-
ine TIMI flow grade 3 in this group, and the difference in
nal TIMI flow grade 3 was less pronounced when it was
djusted for baseline TIMI flow grade (Tables 3 to 5).
Table 1. Baseline Demographic and Clinical C
Characteristics
Age (yrs), mean
Interquartile range
Male gender
Diabetes mellitus, any
Insulin-dependent
Hypertension requiring medication
Dyslipidemia requiring medication
Smoker, past yr
Prior coronary artery disease
Cardiogenic shock at time of consent
Prior stroke
Rescue after failed thrombolysis
Prior percutaneous intervention in target vessel
Time from symptom onset to emergency dept (h), m
Median
Interquartile range
Time from emergency dept to randomization (h), m
Median
Interquartile range
Total procedure time (min), mean
Median
Range
Eptifibatide, before or during the procedure
*Number of patients (%), unless otherwise indicated.
RT  rheolytic thrombectomy.here were no significant differences between groups in inal TMP blush or corrected TIMI frame count. Angiog-
aphic complication rates were low and were similar in both
roups (Tables 3 and 4).
T-segment resolution. Baseline and 90-min 12-lead
CGs that were deemed technically adequate for ST-
egment analysis were available in 176 patients in the
djunct RT group and 164 patients in the PCI alone group.
n ST-segment resolution 70% occurred in 105 patients
60%) in the adjunct RT group and in 111 patients (68%)
reated with PCI alone (p  0.14). An ST-segment
esolution of 30% to 70% occurred in 50 patients (28%)
reated with adjunct RT and 35 patients (21%) treated with
CI alone (p  0.17), and ST-segment resolution 30%
ccurred in 21 patients (12%) treated with adjunct RT and
8 patients (11%) treated with PCI alone (p  0.87).
nfarct size. The primary study end point, Tc 99m sesta-
ibi infarct size, was significantly greater in the adjunct RT
roup (Table 6). By subgroup analysis, this difference was
rimarily driven by differences in inferior infarct size, and
here were no significant differences in anterior infarct
ize between groups. Ejection fraction was similar in both
roups.
dverse events to 30 days. There were no intraprocedure
eaths, strokes, or emergency CABG surgeries. Adverse
vents to 30 days are shown in Table 7. Major adverse
ardiac events were significantly greater in the adjunct RT
roup, attributable to a higher mortality rate in this group.
mong the patients who died, final TIMI flow grade 3 was
chieved in all but 1 patient, who was assigned to adjunct
T treatment, but had unsuccessful reperfusion due to
cteristics*
RT
(n  240)
Control
(n  240)
p
Value
60.0 59.9 0.92
51.0–69.0 49.0–70.0
182 (75.8) 178 (74.2) 0.75
40 (16.7) 38 (15.8) 0.81
10 (4.2) 6 (2.5) 0.27
103 (42.9) 101 (42.1) 0.93
53 (22.1) 61 (25.4) 0.52
106 (44.2) 108 (45.0) 0.71
42 (17.5) 33 (13.8) 0.26
0 0 —
7 (2.9) 10 (4.2) 0.62
34 (14.2) 32 (13.3) 0.90
10 (4.2) 8 (3.3) 0.81
2.4  3.3 2.5  3.2 0.76
1.5 1.7
0.9–3.0 0.9–2.8
2.7  4.3 2.5  3.2 0.61
1.8 1.7
1.3–2.8 1.2–2.8
75.4  30.9 59.2  26.8 0.001
70.0 55.0
19.0–268.0 8.0–137.0
228 (95.0) 226 (94.2) 0.84hara
ean
eannability to cross the lesion with a guidewire. All TLR
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Thrombectomy and PCI in Acute MI July 18, 2006:244–52vents in both groups were due to subacute stent thrombo-
is. Site-reported complications, including bleeding and
rrhythmia events, occurred with similar frequency between
roups.
ubset of patients with angiographically visible thrombus.
hile RT provided no benefit to reducing final infarct size
n the general STEMI patient sample enrolled, there was
nterest in selective patient subsets, especially those with
ngiographically visible thrombus. A total of 96 patients (50
reated with adjunct RT, and 46 treated with PCI alone)
ad large or moderate baseline thrombus by angiographic
nalysis (excluding total occlusions). In this subset, the
able 2. Baseline Lesion Characteristics and Procedural Data*
Characteristics†
RT
(n  240)
Control
(n  240)
p
Value
umber of major coronary arteries
with 50% stenosis
0.55
1 112 (46.7) 116 (48.3)
2 86 (35.8) 78 (32.5)
3 39 (16.3) 44 (18.3)
nfarct-related artery 0.89
Left anterior descending
coronary artery
91 (38.9) 88 (37.4)
Left circumflex artery 27 (11.5) 25 (10.6)
Left main artery/other 1 (0.40) 1 (0.40)
Right coronary artery 115 (49.1) 121 (51.5)
esion length, mm 0.15
1–10 53 (22.6) 56 (23.8)
10–20 97 (41.5) 82 (34.9)
20 18 (7.7) 29 (12.3)
NA 66 (28.2) 68 (28.9)
alcification, moderate to severe 56 (23.9) 58 (24.7) 0.91
hrombus 0.16
Grade 0 (none) 25 (10.7) 33 (14.0)
Grade 1 (possible) 17 (7.3) 10 (4.3)
Grade 2 (small) 12 (5.1) 21 (8.9)
Grade 3 (moderate) 27 (11.5) 32 (13.6)
Grade 4 (large) 28 (9.8) 14 (6.0)
Grade 5 (total occlusion) 129 (55.1) 124 (52.8)
ngulation 45° 16 (6.8) 25 (10.6) 0.19
ortuosity, moderate to severe 21 (9.0) 15 (6.4) 0.71
CC/AHA lesion class 0.73
A 4 (1.7) 3 (1.3)
B1 12 (5.1) 18 (7.7)
B2 39 (16.7) 39 (16.6)
C 179 (76.5) 175 (74.5)
tents 0.45
None 16 (6.3) 13 (5.3)
1 154 (64.5) 173 (72.1)
2 57 (23.8) 45 (18.8)
3 or more 13 (5.4) 9 (3.8)
emporary pacemaker
(recommended during RT,
per approved labeling)
140 (58.3) 35 (14.6) 0.001
uccessful delivery of RT catheter 229 (95.4) — —
redilation before RT treatment 29 (12.1) — —
rossover to RT treatment 6 (0.25) —
Data shown as number (%); †lesion characteristics analyzed by angiographic core lab,
aseline data available for n 234 in RT group, n 235 in control group. Thrombus
rade scale defined in text.
ACC/AHA  American College of Cardiology/American Heart Association;
T  rheolytic thrombectomy.ean final infarct size was 10.8% in the adjunct RT group,
aompared with 8.1% in the PCI alone group (p 0.23), but
his subset also had a strong trend toward higher baseline
IMI flow grade in the PCI alone group (TIMI flow grade
/1  36.0% in the adjunct RT group vs. 19.6% in the PCI
lone group, and TIMI flow grade 2/3  64.0% in the
djunct RT group vs. 80.4% in the PCI alone group, p 
.11). In this subset, there were 3 MACE events in the
djunct RT group (a death, stent thrombosis, and stroke)
nd no MACE in the PCI alone group (p  0.24). While
hese observations may suggest safety of RT in patients with
ignificant visible thrombus, this subset is too small for
efinitive analysis, and our study was not powered to detect
mall subgroup differences.
able 3. Quantitative Angiographic Analysis*
Characteristics†
RT
(n  234)
Control
(n  235)
p
Value
IMI flow grade 0.13
aseline
Grade 0/1 158 (68.4) 148 (63.2)
Grade 2 29 (12.6) 23 (9.8)
Grade 3 44 (19.0) 63 (26.9)
Grade 3 comparison
Yes 44 (19.0) 63 (26.9)
No 187 (81.0) 171 (73.0)  0.05
inal
Grade 0/1 3 (1.3) 1 (0.4) 0.05
Grade 2 16 (6.9) 6 (2.6)
Grade 3 213 (91.8) 228 (97.0)
Grade 3 comparison
Yes 213 (91.8) 228 (97.0)  0.02
No 19 (8.2) 7 (3.0)
% of patients who improved
over baseline
77.8 71.9 0.17
inal TIMI flow grade when
baseline flow grade  0
0 3 (2.3) 1 (0.8)
1 0 (0.0) 0 (0.0)
2 11 (8.3) 5 (3.8)
3 119 (89.5) 125 (95.4)
hen baseline flow grade  1
0 0 (0.0) 0 (0.0)
1 0 (0.0) 0 (0.0)
2 2 (8.0) 0 (0.0)
3 23 (92.0) 17 (100.0)
hen baseline flow grade  2
0 0 (0.0) 0 (0.0)
1 0 (0.0) 0 (0.0)
2 2 (6.9) 2 (6.9)
3 27 (93.1) 27 (93.1)
hen baseline flow grade  3
0 0 (0.0) 0 (0.0)
1 0 (0.0) 0 (0.0)
2 1 (2.3) 0 (0.0)
3 43 (97.7) 63 (100.0)
inal TIMI flow comparison
stratified by baseline
0.07
Data shown as number (%), unless otherwise indicated; †lesion characteristics
ssessed by angiographic core laboratory, TIMI flow and blush grades defined in text.
RT  rheolytic thrombectomy; TIMI  Thrombolysis In Myocardial Infarction.
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he results of this study demonstrate that, in patients
ith STEMI, the routine adjunctive use of RT did not
educe infarction size compared with primary PCI alone.
inal TIMI flow grade 3 was achieved less often in
atients undergoing adjunct RT. The 30-day MACE rate
as higher in patients treated with adjunct RT, a
ifference primarily attributable to a very low mortality
ate in patients treated with PCI alone. Other angiog-
aphic and electrocardiographic end points were similar
n the 2 groups.
I size. Sestamibi infarct size is associated with subse-
uent patient mortality, and myocardial infarct size has been
sed as a surrogate end point to evaluate reperfusion
trategies in patients with STEMI (16,17). In our study,
nal infarction size was larger in patients treated with
djunct RT, a difference that was more pronounced for
nferior MIs. Recent studies using distal protection devices
Table 4. Quantitative Angiographic Analysis*
Characteristics†
TIMI blush grade
Baseline 0/1
Baseline 2
Baseline 3
Grade 3 comparison
Yes
No
Final 0/1
Final 2
Final 3
Grade 3 comparison
Yes
No
% of patients who improved over baseline
Final TIMI blush grade when baseline
blush grade  0
0
1
2
3
When baseline blush grade  1
0
1
2
3
When baseline blush grade  2
0
1
2
3
When baseline blush grade  3
0
1
2
3
Final TIMI blush comparison stratified by baseline
*Data shown as number (%), unless otherwise indicated; †les
flow and blush grades defined in text.
Abbreviations as in Table 3.n patients with STEMI have also failed to show any benefit g18,19). Whether the delivery of these relatively bulky
evices predisposes to distal embolization requires further
nvestigation. Time to reperfusion is also a powerful pre-
ictor of success in STEMI (20). The longer procedure time
n the RT group may have negated any benefit of thrombus
emoval in these patients. There were 94 randomized
atients (42 in RT group, 52 in PCI alone group) that had
o measurable final infarction. Though the possibility of
mall subendocardial infarction in these patients cannot be
xcluded using the SPECT imaging alone, clinical signifi-
ance of any difference between such small final infarction is
et to be established.
ngiographic outcomes. Final TIMI flow grade 3 is a
redictor of outcomes in STEMI (21). Further, patients
ith established TIMI flow grade 2/3 coronary flow before
CI in acute MI have also been shown to have superior
utcomes (22). In our study, baseline TIMI flow grade 3
as present in significantly more patients in the PCI alone
T (n  234) Control (n  235) p Value
(88.8) 189 (84.0) 0.31
(4.0) 13 (5.8)
(7.2) 23 (10.2)
(7.2) 23 (10.2) 0.32
(92.8) 202 (89.8)
(51.0) 85 (41.7)
(18.4) 44 (21.6) 0.30
(30.6) 75 (36.8)
(30.6) 75 (36.8) 0.21
(69.4) 129 (63.2)
45.3 44.3 0.85
(30.6) 33 (26.0)
(18.8) 17 (13.4)
(18.8) 33 (26.0)
(18.8) 22 (17.3)
(11.1) 0 (0.0) 4 (6.5) 0 (0.0)
(42.6) 0 (0.0) 27 (43.5) 0 (0.0)
(9.3) 2 (8.0) 3 (4.8) 0 (0.0)
(35.22) (92.0) 25 (40.3) 17 (100.0)
(22.2) 2 (15.4)
(0.0) 0 (0.0)
(44.4) 7 (53.8)
(11.1) 4 (30.8)
(0.0) 0 (0.0)
(12.5) 0 (0.0)
(0.0) 0 (0.0)
(87.5) 22 (95.7)
0.44
aracteristics assessed by angiographic core laboratory, TIMIR
198
9
16
16
207
105
38
63
63
143
44
27
27
27
6
23
5
19
2
0
4
1
0
2
0
14
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Thrombectomy and PCI in Acute MI July 18, 2006:244–52he observed differences in final outcomes is unknown. Yet,
espite very high rates of final TIMI epicardial flow grade 3,
MP blush grade 3 was achieved in a minority of patients
n both groups, reflecting the failure of current modalities in
stablishing the normal myocardial perfusion.
Benefits of RT in visibly thrombotic lesions in native
oronary arteries and SVGs have been documented in prior
tudies (4,23,24). In these studies, glycoprotein IIb/IIIa
nhibitors were typically used in only a small percentage of
atients. Use of glycoprotein IIb/IIIa inhibitors has been
able 5. Quantitative Angiographic Analysis and
omplications*
Characteristics†
RT
(n  234)
Control
(n  235)
p
Value
eference vessel diameter, mm
Baseline 2.97  0.56 2.98  0.47 0.81
Final 2.96  0.55 3.00  0.47 0.45
inimal luminal diameter, mm
Baseline 0.26  0.43 0.30  0.45 0.35
Final, within segment 2.28  0.63 2.38  0.54 0.06
Final, within stent 2.69  0.52 2.76  0.44 0.14
ercent diameter stenosis
Baseline 91.26  13.17 89.9  14.8 0.29
After RT 63.5  31.2 —
Final, within segment 23.09  13.75 20.63  11.59 0.05
Final, within stent 8.19  11.59 7.54  9.56 0.52
orrected TIMI frame count
Baseline, mean 105  45 100  49 0.19
Final, mean 35  24 32  21 0.13
Improvement, mean,
baseline versus final
72  46 70  51 0.65
ngiographic complications,
intraprocedure
No reflow 6 (2.6) 5 (2.1) 0.77
Abrupt closure 2 (0.9) 2 (0.9) —
Spasm 1 (0.4) 2 (0.9) 1.00
Dissection 9 (3.8) 6 (2.6) 0.63
Perforation 2 (0.9) 1 (0.4) 1.00
Distal embolization 10 (4.3) 12 (5.1) 0.83
Data shown as number (%), unless otherwise indicated; †lesion characteristics
ssessed by angiographic core laboratory. TIMI flow and blush grades defined in text.
Abbreviations as in Table 3.
able 6. Analysis of Infarct Size by Technetium Tc 99m
estamibi Imaging at 14 to 28 Days*
RT
(n  197)
Control
(n  205)
p
Value
inal infarct size, mean 12.5  12.13 9.8  10.92 0.03
Range 0.0–48.0 0.0–44.0
inal infarct size, anterior MI,
mean
16.5  13.13 15.3  11.96 0.58
Range 0.0–48.0 0.0–44.0
inal infarct size, inferior MI,
mean
10.2  11.1 6.5  8.88 0.001
Range 0.0–41.0 0.0–43.0
jection fraction (%) 51.3  11.53 52.3  10.89 0.38
Anterior MI 48.1  12.12 47.4  9.40 0.72
Inferior MI 53.4  10.78 55.3  10.62 0.19
nd-diastolic volume, mean (ml) 114.6  46.2 108.9  42.2 0.21
nd-systolic volume, mean (ml) 59.6  36.2 54.9  30.4 0.17i
For infarct size and ejection fraction, numbers are mean %  SD.
MI  myocardial infarction; RT  rheolytic thrombectomy.hown to improve outcomes of primary PCI in STEMI
25,26), and their use in the majority of patients in the
resent study may have negated any benefit of direct
hrombectomy in these patients.
lectrocardiographic parameters. Our study showed no
ignificant difference in the percentage of patients who
chieved complete ST-segment resolution at 90 min after
eperfusion. In another study, adjunct treatment with RT
esulted in early ST-segment elevation resolution in 90%
ersus 72% in the stenting only group, p  0.02 (27).
nother study using a different thrombectomy device
howed that a higher degree of early ST-segment resolution
as achieved with thrombectomy, but this difference did not
ersist after 18 h (28).
linical outcomes. The overall 30-day MACE rate was
ignificantly higher in the RT group, a difference driven
rimarily by increased mortality in the RT group (4.6% vs.
.8%, p  0.02). Our study was not powered to detect
ifferences in clinical events, including mortality. Although
he mortality in RT group is similar to mortality in other
linical trials with primary PCI, the mortality rate in the
CI alone group (0.8%) was lower than that seen in other
ontemporary acute MI reperfusion trials in which 30-day
ortality ranged from 1.8% to 6.6% (29–31). A detailed
djudication of deaths did not yield any specific device-
elated concerns. The DSMB requested to review mortality
gain at 6 months, which showed that 3 additional deaths
ad occurred in each group—6-month mortality was 5.8%
able 7. Adverse Events to 30 Days*
Events
RT
(n  240)
Control
(n  240)
p
Value
ACE, total 16 (6.7) 4 (1.7) 0.01
Death 11 (4.6) 2 (0.8) 0.02
Q-wave MI 0 0 —
Stroke 4 (1.7) 2 (0.8) 0.69
Emergent CABG 0 0 —
TLR/SAT 5 (2.1) 1 (0.4) 0.22
leeding
Requiring transfusion 16 (6.7) 17 (7/1) 1.00
GI/GU 11 (4.6) 15 (6.3) 0.55
Retroperitoneal 3 (1.3) 6 (2.5) 0.50
Pericardial
hemorrhage/tamponade
2 (0.8) 0 0.50
ardiogenic shock, post-procedure 0 1 (0.4) 1.00
entricular fibrillation
Pre-procedure 12 (5.0) 5 (2.1) 0.34
During/post-procedure 7 (2.9) 3 (1.3)
entricular tachycardia
Nonsustained 28 (11.7) 19 (7.9) 0.22
Sustained 3 (1.3) 4 (1.7) 1.00
Data shown is number (%) of patients. Events adjudicated by clinical events
ommittee: 30-day MACE, perforations, pericardial hemorrhage/tamponade. Angio-
raphic complications as assessed by angiographic core lab (n  234 for RT group,
 235 for control). All TLR was due to SAT. Other events shown were reported
y site.
CABG  coronary artery bypass grafting; GI  gastrointestinal; GU  genito-
rinary; MACE  major adverse cardiac event; MI  myocardial infarction; RT 
heolytic thrombectomy; SAT  subacute stent thrombosis; TLR  target lesion
evascularization.n the adjunct RT group and 2.1% n the PCI only group,
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July 18, 2006:244–52 Thrombectomy and PCI in Acute MI 0.06. Although any mortality conclusions from a study
ot designed to detect mortality differences should be drawn
ith caution and cannot be considered definitive, increased
ACE in the thrombectomy arm raises concerns regarding
outine use of RT in STEMI.
tudy limitations. Randomization after angiography may
ave introduced selection bias against enrolling high-risk
atients with a large amount of angiographically apparent
hrombus, though no data is available to confirm such bias
n enrollment. Another limitation of the study is that MI
ize rather than myocardial salvage was measured. As a
esult, the effect of a lower baseline TIMI flow grade in
atients treated with adjunct RT cannot be determined. It is
lso difficult to ascertain whether the higher baseline TIMI
ow grades contributed to the very favorable outcomes in
atients treated with PCI alone.
linical implications. Despite high technical success rates,
djunct use of RT in patients with STEMI did not reduce
nfarct size, improve TIMI flow or blush grades, improve
T-segment resolution, and resulted in higher MACE at 30
ays. The increased infarct size and increased mortality in
he RT group raise safety concerns about the routine use of
ngioJet in STEMI, and further studies are needed to
larify safety issues and the possible role of AJ in subgroups
f patients with STEMI, particularly those with large
hrombus burden. Reperfusion injury with interstitial
dema, capillary leakage, and generalized coronary endothe-
ial dysfunction may play a much larger role in poor
yocardial reperfusion.
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